Muhurat Trading Stock Picks: Laurus Labs, Can Fin Homes, Bank of India, Pharma Stocks On Brokerages' Radar

• B&K initiated covergae with a Buy rating and a target price of Rs 1,030

• CDMO will emerge as main earnings driver ahead

• ARV disruption is largely behind; B&K expects steady growth ahead

• Other APIs to complement growth

• Generic formulation – capacity expansion will drive growth

• Morgan Stanley maintained an Overweight and hiked target price to Rs 1,000 from Rs 970

• Can Fin Homes surprised positively on NIM and asset quality in Q2

• Can Fin's loan growth pressures have driven down valuations

• Return on Equity is 15% in financial year 2028 is still attractive relative to many mid- and small-sized NBFCs for a secured business

• Valuation is attractive in this context

• Morgan Stanley maintained an underweight, and hiked target price to Rs 120 from Rs 110.

• Net Interest Margin declined offset by strong asset quality

• Second-quarter NIM declined on the quarter by 14 basis points

• RoA, however, was strong at 0.9% led by very low credit costs and strong fee and other income

• Raise estimates and PT to reflect the beat

• Stay Underweight as we expect RoA to be pressured once credit costs normalize

• Third-quarter of calendar year residential sales units down, value Up

• Number of units sold in the September quarter in the top six cities (96K) and Pan-India (145K) declined QoQ and YoY

• The top five developers also gained share

• Price growth slowed but stayed in the mid-single digits YoY

• Jefferies maintained a buy with target price of Rs 575

• Sunteck's pre-sales jumped 34% in Sep'qtr, taking 1H pre-sales up 32% YoY

• Management highlighted its super-luxury push on the call with a large Rs 20,000 crore pipeline

• Business development has remained steady

• Rs 2,300 crore worth of projects signed YTD and a few major additions expected later in the year

• Stock trading at 36% discount to NAV

Blue Jet – Upgrade to Buy from Add; Cut Target Price to Rs 825 from Rs 900

Piramal Pharma – Maintain Buy; Hike Target Price to Rs 325 from Rs 305

New molecules to spice up the hypercholesterolemia space

Obicetrapib—Piramal Pharma’s gain is Blue Jet’s loss